Hypertensive Encephalopathy: A Comprehensive Review
Article Sidebar
Main Article Content
Abstract
The handling of hypertensive encephalopathy - an urgent medical situation marked by sharp neurological symptoms caused due to severe hypertension-driven brain malfunction - is critical. This overview aims to dissect extensively, the mechanisms causing the disease, the various clinical signs it reflects, how it is typically investigated, and the most efficient management methods. Bringing into focus how patients fare, we highlight the most recent scholarly studies and pragmatic guidelines. As such, we aim to deepen the understanding of healthcare professionals about hypertensive encephalopathy in order to optimize patient treatment. Overall, a multidisciplinary approach involving neurologists, intensivists, and other specialists is often required to effectively manage hypertensive encephalopathy. Early recognition, accurate diagnosis, and aggressive blood pressure control are key elements in optimizing outcomes and preventing long-term complications in patients with hypertensive encephalopathy.
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
All open access articles published in the journal are distributed under the terms of the CC-BY-NC-SA 4.0 license (Creative Commons Attribution-Non-commercial-ShareAlike 4.0 International License) which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes, provided the original work is properly cited and distributed under the same license (ShareAlike). Under Creative Commons, authors retain copyright in their articles.
References
Xie F, Cai Y, Huang L, Hao J, Ling T, Richard SA. Obstructive ureteric calculus with superimposed infections causing reversible posterior leukoencephalopathy syndrome: A case report. Medicine. 2021 Apr 4;100(16).
Paulson OB, Strandgaard S, Edvinsson L. Cerebral, autoregulation. Cerebrovascular and brain metabolism reviews. 1990 Jan 1;2(2):161-92.
Schwartz RB. Hyperperfusion encephalopathies: hypertensive encephalopathy and related conditions. The neurologist. 2002 Jan 1;8(1):22-34.
Miller JB, Suchdev K, Jayaprakash N, Hrabec D, Sood A, Sharma S, Levy PD. New developments in hypertensive encephalopathy. Current hypertension reports. 2018 Feb;20:1-7.
Qureshi AI. Acute hypertensive response in patients with stroke. pathophysiology and management. Circulation. 2008 Jul 8;118(2):176-87.
Armstead WM. Cerebral blood flow autoregulation and dysautoregulation. Anesthesiology clinics. 2016 Sep 1;34(3):465-77.
Oppenheimer BS, FISHBERG AM. Hypertensive encephalopathy. Archives of Internal Medicine. 1928 Feb 1;41(2):264-78.
Price RS, Kasner SE. Hypertension and hypertensive encephalopathy. Handbook of clinical neurology. 2014 Jan 1;119:161-7.
Finnerty Jr FA. Hypertensive encephalopathy. The American journal of medicine. 1972 May 1;52(5):672-8.
Dinsdale HB. Hypertensive encephalopathy. Stroke. 1982 Sep;13(5):717-9.
Chester EM, Agamanolis DP, Banker BQ, Victor M. Hypertensive encephalopathy: a clinicopathologic study of 20 cases. Neurology. 1978 Sep 1;28(9):928.
Williams O, Brust JC. Hypertensive encephalopathy. Current Treatment Options in Cardiovascular Medicine. 2004 Jun;6(3):209-16.
Donaldson JO. Eclamptic hypertensive encephalopathy. InSeminars in neurology 1988 Sep (Vol. 8, No. 03, pp. 230-233). © 1988 by Thieme Medical Publishers, Inc.
Pavlakis SG, Frank Y, Chusid R. Topical review: hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: three names for an old syndrome. Journal of child neurology. 1999 May;14(5):277-81.
Chawla R, Smith D, Marik PE. Near fatal posterior reversible encephalopathy syndrome complicating chronic liver failure and treated by induced hypothermia and dialysis: a case report. Journal of Medical Case Reports. 2009 Dec;3(1):1-4.
Patel R, Ansari A, Grim CE. Prognosis and predisposing factors for essential malignant hypertension in predominantly black patients. The American journal of cardiology. 1990 Oct 1;66(10):868-9.
Sharifian M. Hypertensive encephalopathy. Iranian journal of child neurology. 2012;6(3):1.
Auer LM. The pathogenesis of hypertensive encephalopathy: experimental data and their clinical relevance with special reference to neurosurgical patients.
Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S, Magee LA, Rana S, Vermunt JV, August P. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association. Hypertension. 2022 Feb;79(2):e21-41.
Mahfoud F, Böhm M, Bongarth CM, Bosch R, Schmieder RE, Schunkert H, Stellbrink C, Trenkwalder P, Vonend O, Weil J, Kreutz R. Comments on the guidelines (2018) of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) on the management of arterial hypertension. Der Kardiologe. 2019 Feb;13:17-23.
Chawla R, Smith D, Marik PE. Near fatal posterior reversible encephalopathy syndrome complicating chronic liver failure and treated by induced hypothermia and dialysis: a case report. Journal of Medical Case Reports. 2009 Dec;3(1):1-4.
Gifford Jr RW, Westbrook E. Hypertensive encephalopathy: mechanisms, clinical features, and treatment. Progress in Cardiovascular Diseases. 1974 Sep 1;17(2):115-24.
Vaughan CJ, Delanty N. Hypertensive emergencies. The Lancet. 2000 Jul 29;356(9227):411-7.
MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1983 Jul 8;3(4):193-217.
Brogden RN, Heel RC, Speight TM, Avery GS. Labetalol: a review of its pharmacology and therapeutic use in hypertension. Drugs. 1978 Apr;15:251-70.
Richards DA, Prichard BN. Clinical pharmacology of labetalol. British Journal of Clinical Pharmacology. 1979;8(Suppl 2):89S.
Martin LE, Hopkins R, Bland R. Metabolism of labetalol by animals and man. British journal of clinical pharmacology. 1976 Aug 1;3(4 Suppl 3):695-710.
Wiest DB, Haney JS. Clinical pharmacokinetics and therapeutic efficacy of esmolol. Clinical pharmacokinetics. 2012 Jun;51:347-56.
Wiest D. Esmolol: a review of its therapeutic efficacy and pharmacokinetic characteristics. Clinical pharmacokinetics. 1995 Mar;28(3):190-202.
Koch-Weser J. Hydralazine. New England Journal of Medicine. 1976 Aug 5;295(6):320-3.
Kandler MR, Mah GT, Tejani AM, Stabler SN, Salzwedel DM. Hydralazine for essential hypertension. Cochrane database of systematic reviews. 2011(11).
Magee LA, Cham C, Waterman EJ, Ohlsson A, Von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. Bmj. 2003 Oct 23;327(7421):955.
Natesh R, Schwager SL, Evans HR, Sturrock ED, Acharya KR. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry. 2004 Jul 13;43(27):8718-24.
Hockings N, Ajayi AA, Reid JL. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. British journal of clinical pharmacolo gy. 1986 Apr;21(4):341-8.
Strauss R, Gavras I, Vlahakos D, Gavras H. Enalaprilat in hypertensive emergencies. The Journal of Clinical Pharmacology. 1986 Jan;26(1):39-43.
Gould L, Reddy CV. Phentolamine. American Heart Journal. 1976 Sep 1;92(3):397-402.
Taylor SH, Sutherland GR, MacKenzie GJ, Staunton HP, Donald KW. The circulatory effects of intravenous phentolamine in man. Circulation. 1965 May;31(5):741-54.